Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection

Journal of Viral Hepatitis

Volumn 14, Issue 1, 2007, Pages 29-35

  Westin, J ^a   Lagging, M ^a   Dhillon, A P ^b   Norkrans, G ^a   Romero, A I ^a   Pawlotsky, J M ^c   Zeuzem, S ^d   Schalm, S W ^e   Verheij Hart, E ^e   Negro, F ^f   Missale, G ^g   Neumann, A U ^h   Hellstrand, K ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c HENRI MONDOR HOSPITAL   (France)

^d SAARLAND UNIVERSITY   (Germany)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF GENEVA   (Switzerland)

^g UNIVERSITY HOSPITAL OF PARMA   (Italy)

^h BAR ILAN UNIVERSITY   (Israel)

Author keywords

Antiviral treatment; Hepatitis C; Liver steatosis; Treatment outcome; Viral kinetics

Indexed keywords

PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; FATTY LIVER; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MALE; METABOLIC PARAMETERS; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BIOPSY; FATTY LIVER; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; KAPLAN-MEIERS ESTIMATE; KINETICS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 33845737858     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00777.x     Document Type: Article

References (27)

1. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1992; 15(4): 567-571.
2. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992; 15(4): 572-577.
3. Hourigan LF, Macdonald GA, Purdie D et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29(4): 1215-1219.
4. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33(6): 1358-1364.
5. Rubbia-Brandt L, Quadri R, Abid K et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33(1): 106-115.
6. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36(3): 729-736.
7. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34(3): 428-434.
8. Castera L, Hezode C, Roudot-Thoraval F et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003; 52(2): 288-292.
9. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002; 37(6): 837-842.
10. Rubbia-Brandt L, Fabris P, Paganin S et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004; 53(3): 406-412.
11. Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005; 41(1): 82-87.
12. Mihm S, Fayyazi A, Hartmann H, Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997; 25(3): 735-739.
13. Hofer H, Bankl HC, Wrba F et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 2002; 97(11): 2880-2885.
14. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002; 36(5): 1266-1272.
15. Castera L, Hezode C, Roudot-Thoraval F et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 2004; 53(3): 420-424.
16. Poynard T, Ratziu V, McHutchison J et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38(1): 75-85.
17. Patton HM, Patel K, Behling C et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40(3): 484-490.
18. Thomopoulos KC, Theocharis GJ, Tsamantas AC et al. Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2005; 17(2): 149-153.
19. Zeuzem S, Pawlotsky JM, Lukasiewicz E et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005; 43(2): 250-257.
20. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22(6): 696-699.
21. Perlemuter G, Sabile A, Letteron P et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. Faseb J 2002; 16(2): 185-194.
22. Cholet F, Nousbaum JB, Richecoeur M et al. Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients. Gastroenterol Clin Biol 2004; 28(3): 272-278.
23. Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40(6): 993-999.
24. Akuta N, Suzuki F, Suzuki Y et al. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis. J Med Virol 2005; 75(4): 550-558.
25. Romero-Gomez M, Del Mar Viloria M, Andrade RJ et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128(3): 636-641.
26. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38(3): 639-644.
27. Hickman IJ, Clouston AD, Macdonald GA et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51(1): 89-94.